Please assess the completion status of the following clinical trial:

Trial Title: Effect of Erythropoietin on Neurodevelopmental Outcomes in Very Preterm Infants With Intraventricular Hemorrhage

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Preterm infants admitted to NICU ≤ 32 weeks gestation at birth~* Birth weight less than 1500 g~* Less than 72 hours of life at time of enrolment~* Diagnosed as IVH by head ultrasound~* Written informed consent of parent or guardian~Exclusion Criteria:~* Genetic metabolic diseases~* Congenital abnormalities~* Polycythaemia (Hct \> 65%) within first 24 hours of life~* Thrombocytopenia (platelets \< 50K cells/microL) within first 24 hours of life~* Unstable vital signs (such as respiration and circulation failure)

- Gender: ALL
- Minimum Age: None
- Maximum Age: 72 Hours
- Healthy Volunteers: f

Study Arms:
- Erythropoietin (Type: EXPERIMENTAL): EPO is administered 500IU/kg, intravenously after diagnosis of IVH within 72h after birth, and every other day for 2 weeks. Recombinant human erythropoietin was configured by the hospital pharmacy intravenous Centre Configuration, melted configured with saline to 1ml/kg solution.
- Normal saline (Type: PLACEBO_COMPARATOR): Normal saline is administered the same volume with EPO, intravenously after diagnosis of IVH within 72h after birth, and every other day for 2 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).